News
The efficacy and safety of currently approved and pipeline medications for moderate-to-severe hidradenitis suppurativa (HS) ...
Novartis announced top-line results from the phase III GCAptAIN study evaluating Cosentyx (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the study, Cosentyx ...
“While the phase 3 results of GCAptAIN did not replicate the positive outcomes observed in the phase 2 trial, we remain committed to continuing to drive scientific progress and deepening the ...
NVS' Cosentyx fails to meet its primary goal in a phase III study for giant cell arteritis, despite favorable safety data.
Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).
A new study links abdominal fat, especially in women, to increased risk of psoriasis, regardless of genetic predisposition, ...
Secukinumab, an anti-IL-17A monoclonal antibody biologic drug, showed promise as a treatment for patients with active ankylosing spondylitis, according to new research. Ankylosing spondylitis, or ...
Secukinumab treatment was associated with lower odds of enthesophyte progression (odds ratio [OR], 0.264; P = .030) and higher odds of partial healing of erosion (OR, 2.882; P = .027).
The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1Safety in GCA patients was consistent with known safety profile o ...
Corticosteroids, commonly used in SLE, can exacerbate psoriasis, while phototherapy for psoriasis may trigger lupus flares. In this case, secukinumab, an IL-17A inhibitor, provided effective control ...
9mon
Oprah Daily on MSNMy Journey With HS, From Adolescence To AdulthoodHidradenitis suppurativa is a chronic, systemic, and often painful skin condition. Here’s what it’s like living with it.
A total of 173 and 162 patients received secukinumab at 6 and 12 months, respectively. Mean patient age was 48.45 years; 56% of patients were men and 20% of patients had PsA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results